108 related articles for article (PubMed ID: 9314119)
1. Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon.
Shiratori Y; Kato N; Yokosuka O; Hashimoto E; Hayashi N; Nakamura A; Asada M; Kuroda H; Ohkubo H; Arakawa Y; Iwama A; Omata M
J Hepatol; 1997 Sep; 27(3):437-44. PubMed ID: 9314119
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
[TBL] [Abstract][Full Text] [Related]
4. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon.
Trabaud MA; Bailly F; Si-Ahmed SN; Chevallier P; Sepetjan M; Colucci G; Trépo C
J Med Virol; 1997 May; 52(1):105-12. PubMed ID: 9131466
[TBL] [Abstract][Full Text] [Related]
6. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon alpha.
Kobayashi M; Chayama K; Arase Y; Tsubota A; Saitoh S; Suzuki Y; Kobayashi M; Kobayashi M; Ikeda K; Matsuda M; Koike H; Hashimoto M; Kumada H
J Gastroenterol; 1999 Feb; 34(1):94-9. PubMed ID: 10204617
[TBL] [Abstract][Full Text] [Related]
8. [Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy].
Higashimoto M; Takahashi M; Jokyu R; Saito H
Rinsho Byori; 2006 Feb; 54(2):111-5. PubMed ID: 16548229
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia.
Furusyo N; Hayashi J; Kashiwagi K; Nakashima H; Nabeshima S; Sawayama Y; Kinukawa N; Kashiwagi S
Dig Dis Sci; 2002 Mar; 47(3):535-42. PubMed ID: 11911338
[TBL] [Abstract][Full Text] [Related]
10. Determination of serum hepatitis C virus (HCV) core protein using a novel approach for quantitative evaluation of HCV viraemia in anti-HCV-positive patients.
Komatsu F; Takasaki K
Liver; 1999 Oct; 19(5):375-80. PubMed ID: 10533794
[TBL] [Abstract][Full Text] [Related]
11. Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA.
Yu ML; Chuang WL; Chen SC; Lin ZY; Hsieh MY; Wang LY; Chang WY
J Clin Pathol; 1999 Nov; 52(11):807-11. PubMed ID: 10690168
[TBL] [Abstract][Full Text] [Related]
12. Accurate prediction of response to interferon therapy by repeated measurement of hepatitis C virus core protein in patients with chronic hepatitis C.
Nishiguchi S; Enomoto M; Tanaka M; Fukuda K; Tamori A; Habu D; Takeda T; Shiomi S; Tanaka T; Yano Y; Otani S
Intervirology; 2002; 45(2):105-10. PubMed ID: 12145543
[TBL] [Abstract][Full Text] [Related]
13. Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads.
Enomoto M; Nishiguchi S; Tamori A; Kohmoto M; Habu D; Sakaguchi H; Takeda T; Kawada N; Seki S; Shiomi S
J Med Virol; 2005 Sep; 77(1):77-82. PubMed ID: 16032731
[TBL] [Abstract][Full Text] [Related]
14. Quantitative measurement of HCV RNA in the serum: a comparison of three assays based on different principles.
Ichijo T; Matsumoto A; Kobayashi M; Furihata K; Tanaka E
J Gastroenterol Hepatol; 1997 Jul; 12(7):500-6. PubMed ID: 9257240
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.
Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
Scand J Infect Dis; 1998; 30(5):441-6. PubMed ID: 10066040
[TBL] [Abstract][Full Text] [Related]
16. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications.
Gretch DR; dela Rosa C; Carithers RL; Willson RA; Williams B; Corey L
Ann Intern Med; 1995 Sep; 123(5):321-9. PubMed ID: 7542853
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of hepatitis C virus RNA predict non-response to interferon therapy: comparison of two commercial assays.
Soffredini R; Rumi MG; Del Ninno E; Parravicini ML; Russo A; Colombo M
J Viral Hepat; 1999 Jan; 6(1):65-71. PubMed ID: 10847132
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0.
Yokosuka O; Kawai S; Suzuki Y; Fukai K; Imazeki F; Kanda T; Tada M; Mikata R; Hata A; Saisho H
Liver Int; 2005 Dec; 25(6):1136-41. PubMed ID: 16343063
[TBL] [Abstract][Full Text] [Related]
19. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alpha therapy in chronic hepatitis C patients.
Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S; Orito E; Mizokami M
J Med Virol; 1996 Apr; 48(4):354-9. PubMed ID: 8699168
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.
Vermehren J; Susser S; Berger A; Perner D; Peiffer KH; Allwinn R; Zeuzem S; Sarrazin C
J Clin Virol; 2012 Sep; 55(1):17-22. PubMed ID: 22698697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
